Cambridge Investment Research Advisors, Inc. Evolus, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 29, 2020	SELL	$3.03 - $5.48 $44,344 - $80,199	-14,635 Closed	0 $0
Q2 2020 Jul 27, 2020	BUY	$3.53 - $6.17 $8,517 - $14,888	2,413 Added 19.74%	14,635 $77,000
Q1 2020 May 08, 2020	BUY	$3.53 - $12.21 $43,143 - $149,230	12,222 New	12,222 $50,000

Others Institutions Holding EOLS

# of Institutions

168

Shares Held

47.8M

Call Options Held

130K

Put Options Held

51K

Perceptive Advisors LLC New York, NY

5.36M
Shares

$58.1 Million
2.27% of portfolio
Tang Capital Management LLC San Diego, CA

4.85M
Shares

$52.5 Million
6.69% of portfolio
Black Rock Inc. New York, NY

4.01M
Shares

$43.4 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

3.2M
Shares

$34.6 Million
0.0% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

2.82M
Shares

$30.6 Million
2.72% of portfolio

View Full List

About Evolus, Inc.

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $608M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

More about EOLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account